International Journal of Heart Failure

The Korean Society of Heart Failure (대한심부전학회)
권호 표지
DOI QR코드

DOI QR Code

Current and Future of Heart Failure Care in Asia

  • Sang Gune K. Yoo (Cardiovascular Division, Department of Internal Medicine, Washington University in St. Louis) ;
  • Mohammed O. Ahmed (Cardiovascular Division, Department of Internal Medicine, Washington University in St. Louis) ;
  • Nancy K. Sweitzer (Cardiovascular Division, Department of Internal Medicine, Washington University in St. Louis)
  • Received : 2024.06.13
  • Accepted : 2024.08.15
  • Published : 2024.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Heart failure (HF) is a significant global health concern, particularly in Asia, where over half of the world's population resides. Despite advances in treatment, the burden of HF is expected to rise in the region due to the aging population and an increase in non-communicable diseases associated with HF risk. This narrative review examines the current state of HF in Asia, highlighting differences in treatment utilization, underrepresentation of Asian individuals in clinical trials, emerging therapies, and implementation strategies, including the potential use of polypills and the need for expanded HF training opportunities for healthcare providers.

Keywords

References

  1. Zhao D. Epidemiological features of cardiovascular disease in Asia. JACC Asia 2021;1:1-13.
  2. Mentz RJ, Roessig L, Greenberg BH, et al. Heart failure clinical trials in east and southeast Asia: understanding the importance and defining the next steps. JACC Heart Fail 2016;4:419-27.
  3. Atherton JJ, Hayward CS, Wan Ahmad WA, et al. Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 2012;18:82-8.
  4. Lam CSP, Anand I, Zhang S, et al. Asian sudden cardiac death in heart failure (ASIAN-HF) registry. Eur J Heart Fail 2013;15:928-36.
  5. Tromp J, Tay WT, Ouwerkerk W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. PLoS Med 2018;15:e1002541.
  6. Vijay A, Tay WT, Teng TK, et al. Polypill eligibility for patients with heart failure with reduced ejection fraction in the ASIAN-HF registry: a cross-sectional analysis. Glob Heart 2023;18:33.
  7. Bragazzi NL, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol 2021;28:1682-90.
  8. Feng J, Zhang Y, Zhang J. Epidemiology and burden of heart failure in Asia. JACC Asia 2024;4:249-64.
  9. Lee CJ, Lee H, Yoon M, et al. Heart failure statistics 2024 update: a report from the Korean Society of Heart Failure. Int J Heart Fail 2024;6:56-69.
  10. Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure registry (KorAHF). Korean Circ J 2017;47:341-53.
  11. Yoo SGK, Lam CSP, Sweitzer NK. "Asian" heart failure. Circulation 2024;150:177-9.
  12. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Korean Circ J 2023;53:217-38.
  13. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
  14. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.
  15. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
  16. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
  17. Azzopardi R, Nicholls SJ, Nerlekar N, et al. Asia-Pacific investigators and Asian enrollment in cardiometabolic trials: insights from publications between 2011 and 2020. JACC Asia 2023;3:724-35.
  18. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008.
  19. Kristensen SL, Martinez F, Jhund PS, et al. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J 2016;37:3167-74.
  20. Kondo T, Wang X, Yang M, et al. Efficacy of dapagliflozin according to geographic location of patients with heart failure. J Am Coll Cardiol 2023;82:1014-26.
  21. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-92.
  22. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 2015;131:34-42.
  23. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-84.
  24. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32.
  25. Chandramouli C, Tay WT, Bamadhaj NS, et al. Association of obesity with heart failure outcomes in 11 Asian regions: a cohort study. PLoS Med 2019;16:e1002916.
  26. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
  27. Arnold SV, Tang F, Cooper A, et al. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocr Disord 2022;22:111.
  28. Teng TK, Tromp J, Tay WT, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health 2018;6:e1008-18.
  29. Chia YMF, Teng TK, Tan ESJ, et al. Disparity between indications for and utilization of implantable cardioverter defibrillators in Asian patients with heart failure. Circ Cardiovasc Qual Outcomes 2017;10:e003651.
  30. Ueda N, Noda T, Kusano K, Yasuda S, Kurita T, Shimizu W. Use of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in Asia. JACC Asia 2023;3:335-45.
  31. Golwala H, Bajaj NS, Arora G, Arora P. Implantable cardioverter-defibrillator for nonischemic cardiomyopathy: an updated meta-analysis. Circulation 2017;135:201-3.
  32. Agarwal A, Tromp J, Almahmeed W, et al. Toward a universal definition of etiologies in heart failure: categorizing causes and advancing registry science. Circ Heart Fail 2024;17:e011095.
  33. Kwan TW, Wong SS, Hong Y, et al. Epidemiology of diabetes and atherosclerotic cardiovascular disease among Asian American adults: implications, management, and future directions: a scientific statement from the American Heart Association. Circulation 2023;148:74-94.
  34. Tan K, Foo R, Loh M. Cardiomyopathy in Asian cohorts: genetic and epigenetic insights. Circ Genom Precis Med 2023;16:496-506.
  35. Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Hear J 2015;36:1123-35a.
  36. Moon I, Lee SY, Kim HK, et al. Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: a nationwide population-based cohort study. PLoS One 2020;15:e0227012. 
  37. Tomar S, Klinzing DC, Chen CK, et al. Causative variants for inherited cardiac conditions in a Southeast Asian population cohort. Circ Genom Precis Med 2022;15:e003536.
  38. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022;400:1938-52.
  39. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;28:568-74.
  40. Chan WV, Pearson TA, Bennett GC, et al. ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI implementation science work group: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2017;69:1076-92.
  41. Pandey A, Keshvani N, Wang TJ. Should polypills be used for heart failure with reduced ejection fraction? Circulation 2022;146:276-8.
  42. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387:967-77.
  43. Huffman MD, Yusuf S. Polypills: essential medicines for cardiovascular disease secondary prevention? J Am Coll Cardiol 2014;63:1368-70.
  44. Reyes EB, Ha JW, Firdaus I, et al. Heart failure across Asia: same healthcare burden but differences in organization of care. Int J Cardiol 2016;223:163-7.
  45. Raja Shariff RE, Hui Beng K, Mohd Ghazi A. The great Asian mismatch: training versus care in heart failure. J Card Fail 2022;28:1378-81.
  46. Echols MR, Ogunniyi MO. Role and contribution of the general heart failure cardiologist: further expansion of the multidisciplinary heart failure approach. J Card Fail 2022;28:659-63.
  47. Il'Giovine ZJ, Menon V. The intersection of heart failure and critical care: the contemporary cardiac intensive care unit and the opportunity for a unique training pathway. J Card Fail 2021;27:1152-5.
  48. Blumer V, Kittleson MM, Teerlink JR, et al. A roadmap to reinvigorating training pathways focused on the care of patients with heart failure: shifting from failure to function. J Card Fail 2023;29:527-30.
  49. Yao W, Cheang I, Liao S, et al. Study protocol for a randomized controlled trial: Qiliqiangxin in heart failUre: assESsment of reduction in morTality (QUEST). BMC Complement Med Ther 2020;20:38.
  50. Yang Y, Li X, Chen G, et al. Traditional Chinese Medicine Compound (Tongxinluo) and clinical outcomes of patients with acute myocardial infarction: the CTS-AMI randomized clinical trial. JAMA 2023;330:1534-45.
  51. Bach RG. Traditional Chinese medicine meets evidence-based medicine in the acutely infarcted heart. JAMA 2023;330:1529-30.
  52. Prabhakaran D, Chandrasekaran AM, Singh K, et al. Yoga-based cardiac rehabilitation after acute myocardial infarction: a randomized trial. J Am Coll Cardiol 2020;75:1551-61.
  53. Yeh GY, McCarthy EP, Wayne PM, et al. Tai chi exercise in patients with chronic heart failure: a randomized clinical trial. Arch Intern Med 2011;171:750-7.